Wednesday, September 23, 2020 3:53:20 AM
misiu143.. Learning 53.. I’m in Congruence..!!!
Your point on NO COMPETITION in the LONG HAULERS arena.. is well taken..AND TRUE..In fact if done appropriately..may offer a back door entry for Leronlimab into the Covid Space..!!!
My concern as I stated ..is the PROTOCOL..!!! After decades of attending Investigator Meetings..Where the Protocol is discussed at nauseum with all the participating Physician Investigators..My opinion of the Pharma D who write these protocols..is VERY LOW.. In fact I think they’re PATHETIC..These include ALL major Pharmaceuticals..Merck..Pfizer..Sanofi..Etc..
Mistakes made in the Protocol..are often pointed out by Physicians..in the Investigator meetings..Ignored by the Pharmaceuticals..And paid dearly for in Protocol Amendments..that delay the completion of the trial by months.. in some cases ..years.. !!!
After seeing the farce of the Mild to Moderate Corona Trial..My opinion remains unchanged..!!!
My concern..as I stated in my previous post..is that Leronlimab not suffer the consequences of a poorly thought out or written Protocol..!!! Believe me..I’ve seen enough of those in my career..!!!
As always..It’s GREAT to be on this Board.. AND .. Do appreciate ALL the members giving their honest opinions..and sharing their expertise..!!!
Your point on NO COMPETITION in the LONG HAULERS arena.. is well taken..AND TRUE..In fact if done appropriately..may offer a back door entry for Leronlimab into the Covid Space..!!!
My concern as I stated ..is the PROTOCOL..!!! After decades of attending Investigator Meetings..Where the Protocol is discussed at nauseum with all the participating Physician Investigators..My opinion of the Pharma D who write these protocols..is VERY LOW.. In fact I think they’re PATHETIC..These include ALL major Pharmaceuticals..Merck..Pfizer..Sanofi..Etc..
Mistakes made in the Protocol..are often pointed out by Physicians..in the Investigator meetings..Ignored by the Pharmaceuticals..And paid dearly for in Protocol Amendments..that delay the completion of the trial by months.. in some cases ..years.. !!!
After seeing the farce of the Mild to Moderate Corona Trial..My opinion remains unchanged..!!!
My concern..as I stated in my previous post..is that Leronlimab not suffer the consequences of a poorly thought out or written Protocol..!!! Believe me..I’ve seen enough of those in my career..!!!
As always..It’s GREAT to be on this Board.. AND .. Do appreciate ALL the members giving their honest opinions..and sharing their expertise..!!!
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
